Sickle Cell Anaemia clinical trials

Explore recruiting sickle cell anaemia clinical trials.

Recruiting sickle cell anaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sickle Cell Anaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Morphine PCA vs Morphine and Lidocaine PCA for the treatment of vaso-occlusive crisis-related pain in sickle-cell anaemia patients: a prospective, randomized, double blind monocentric trial.

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype

Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

The Effect of Mitapivat on Cerebral Perfusion and Oxygen Metabolism in Sickle Cell Disease

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Clairance de la morPHinE et filtration glomérulaire chez le Drepanocytaire en crise en REAnimation_PHEDREA

France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease

Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease

Belgium, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Sickle Cell Anaemia trials by city

Sickle Cell Anaemia in Toronto Sickle Cell Anaemia in Vancouver Sickle Cell Anaemia in Montreal Sickle Cell Anaemia in Calgary Sickle Cell Anaemia in Edmonton Sickle Cell Anaemia in Ottawa Sickle Cell Anaemia in Winnipeg Sickle Cell Anaemia in Quebec City Sickle Cell Anaemia in Hamilton Sickle Cell Anaemia in Kitchener Sickle Cell Anaemia in London Sickle Cell Anaemia in Halifax Sickle Cell Anaemia in New York Sickle Cell Anaemia in Los Angeles Sickle Cell Anaemia in Chicago Sickle Cell Anaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease